Yong Liu Selected Research

metabotropic glutamate receptor 4

1/2021	Activation of metabotropic glutamate receptor 4 regulates proliferation and neural differentiation in neural stem/progenitor cells of the rat subventricular zone and increases phosphatase and tensin homolog protein expression.
1/2019	Activation of type 4 metabotropic glutamate receptor promotes cell apoptosis and inhibits proliferation in bladder cancer.
1/2018	Activity of Metabotropic Glutamate Receptor 4 Suppresses Proliferation and Promotes Apoptosis With Inhibition of Gli-1 in Human Glioblastoma Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yong Liu Research Topics

Disease

334	Neoplasms (Cancer) 12/2022 - 01/2002
75	Infections 08/2022 - 09/2002
71	Inflammation (Inflammations) 01/2022 - 01/2002
56	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2002
51	Fibrosis (Cirrhosis) 07/2022 - 04/2008
46	Hypoxia (Hypoxemia) 07/2022 - 09/2007
41	Acute Kidney Injury (Acute Renal Failure) 03/2022 - 01/2013
37	Ischemia 01/2022 - 07/2003
36	Stomach Neoplasms (Stomach Cancer) 02/2022 - 01/2002
35	Brain Ischemia (Cerebral Ischemia) 01/2021 - 11/2002
32	Insulin Resistance 02/2021 - 11/2007
31	Squamous Cell Carcinoma of Head and Neck 02/2022 - 11/2010
29	Carcinogenesis 07/2022 - 06/2006
29	Hypertension (High Blood Pressure) 02/2022 - 07/2007
29	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2007
28	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 03/2004
28	Obesity 04/2022 - 02/2008
26	Carcinoma (Carcinomatosis) 10/2022 - 04/2002
26	Lung Neoplasms (Lung Cancer) 10/2021 - 12/2003
25	Glioma (Gliomas) 12/2022 - 10/2002
25	Breast Neoplasms (Breast Cancer) 01/2022 - 11/2003
25	Wounds and Injuries (Trauma) 01/2022 - 09/2009
23	Lymphatic Metastasis 01/2020 - 09/2002
22	Atherosclerosis 06/2022 - 04/2005
22	Pain (Aches) 01/2022 - 04/2007
22	Heart Failure 01/2022 - 03/2012
21	Alzheimer Disease (Alzheimer's Disease) 03/2022 - 09/2002
20	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 10/2015
19	COVID-19 02/2022 - 01/2020
19	Cognitive Dysfunction 01/2022 - 01/2014
19	Brain Injuries (Brain Injury) 01/2021 - 02/2006
18	Colorectal Neoplasms (Colorectal Cancer) 09/2022 - 09/2009
18	Liver Cirrhosis (Hepatic Cirrhosis) 06/2022 - 11/2009
18	Status Epilepticus (Complex Partial Status Epilepticus) 02/2022 - 02/2007
18	ST Elevation Myocardial Infarction 01/2022 - 11/2010
18	Chronic Renal Insufficiency 01/2022 - 09/2013
18	Myocardial Infarction 01/2022 - 07/2006
17	Schizophrenia (Dementia Praecox) 10/2022 - 08/2009
17	Stroke (Strokes) 01/2022 - 02/2006
17	Chronic Hepatitis B 01/2022 - 02/2011
16	Diabetes Mellitus 02/2022 - 04/2009
16	Infarction (Infarctions) 01/2021 - 12/2004
16	Nasopharyngeal Carcinoma 03/2018 - 09/2009
15	Cardiovascular Diseases (Cardiovascular Disease) 06/2022 - 04/2015
15	Reperfusion Injury 05/2022 - 06/2007
15	Melanoma (Melanoma, Malignant) 05/2022 - 03/2002
15	Necrosis 01/2021 - 04/2007
14	Pancreatitis 05/2022 - 03/2011
14	Disease Progression 04/2022 - 06/2014
14	Body Weight (Weight, Body) 01/2022 - 09/2006
14	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2021 - 07/2003
13	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 01/2003
13	Prostatic Neoplasms (Prostate Cancer) 07/2021 - 05/2006

Drug/Important Bio-Agent (IBA)

129	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2005
93	Biomarkers (Surrogate Marker)IBA 08/2022 - 05/2006
57	Pharmaceutical PreparationsIBA 06/2022 - 06/2004
52	MicroRNAs (MicroRNA)IBA 08/2022 - 09/2009
48	Messenger RNA (mRNA)IBA 01/2022 - 04/2002
46	Biological ProductsIBA 01/2022 - 03/2002
45	CytokinesIBA 01/2022 - 01/2002
32	Small Interfering RNA (siRNA)IBA 01/2021 - 11/2003
31	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2006
28	DNA (Deoxyribonucleic Acid)IBA 06/2022 - 07/2002
27	Long Noncoding RNAIBA 01/2022 - 03/2014
25	RNA (Ribonucleic Acid)IBA 10/2022 - 01/2011
23	Interleukin-6 (Interleukin 6)IBA 05/2022 - 01/2002
23	EnzymesIBA 03/2022 - 09/2009
21	Indicators and Reagents (Reagents)IBA 12/2021 - 04/2009
21	Insulin (Novolin)FDA Link 10/2021 - 11/2007
20	Retinaldehyde (Retinal)IBA 11/2022 - 07/2009
20	Phosphotransferases (Kinase)IBA 10/2022 - 09/2003
20	AntigensIBA 01/2022 - 01/2002
18	C-Reactive ProteinIBA 01/2022 - 05/2007
18	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 07/2003
17	Oxygen (Dioxygen)IBA 08/2022 - 05/2014
17	Pilocarpine (Ocusert)FDA LinkGeneric 01/2021 - 02/2007
17	Bromodeoxyuridine (BrdU)IBA 01/2021 - 10/2005
17	Therapeutic UsesIBA 01/2021 - 04/2007
16	LigandsIBA 01/2022 - 03/2002
16	LipidsIBA 01/2022 - 11/2007
15	Peptides (Polypeptides)IBA 12/2022 - 02/2006
15	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2022 - 06/2007
15	VaccinesIBA 02/2022 - 11/2006
15	Antiviral Agents (Antivirals)IBA 01/2021 - 09/2007
14	Anti-Bacterial Agents (Antibiotics)IBA 08/2022 - 01/2006
14	CholesterolIBA 06/2022 - 05/2007
14	CreatinineIBA 03/2022 - 01/2013
14	oxidized low density lipoproteinIBA 01/2022 - 09/2005
13	salicylhydroxamic acid (SHAM)IBA 10/2022 - 11/2002
13	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 06/2010
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 01/2002

Therapy/Procedure

147	Therapeutics 06/2022 - 11/2003
52	Percutaneous Coronary Intervention 01/2022 - 05/2012
40	Radiotherapy 07/2022 - 07/2002
37	Drug Therapy (Chemotherapy) 01/2022 - 06/2004
24	Transplantation 01/2022 - 07/2009
21	Immunotherapy 10/2022 - 01/2002
14	Stents 04/2021 - 11/2009
14	Decompression 01/2020 - 09/2009
13	Length of Stay 06/2021 - 01/2012